Management of Scalp Psoriasis with Dactylitis

Introduction to Treatment

The American College of Rheumatology recommends systemic therapy with a TNF inhibitor or other biologic agent for patients with scalp psoriasis and dactylitis, as it addresses both skin and joint manifestations simultaneously, with Level A evidence for treating both dactylitis and psoriasis simultaneously 1, 2

Dactylitis is defined as uniform swelling of a digit due to synovitis, tenosynovitis, enthesitis, and soft-tissue edema, occurring in 16-48% of PsA cases, and is a clinical indicator of disease severity in PsA 1, 3
The presence of dactylitis indicates active inflammatory arthritis requiring disease-modifying treatment to prevent joint damage and disability, with a cumulative negative impact of widespread inflammation at various sites (skin + joints) leading to profound impairment of quality of life and function 1, 4

First-line systemic treatment should be a TNF inhibitor (adalimumab, etanercept, or infliximab), with Level A evidence for treating both dactylitis and psoriasis simultaneously 1, 5
Alternative biologic options with strong evidence include IL-17 inhibitors (secukinumab, ixekizumab, brodalumab), IL-23 inhibitors (guselkumab, risankizumab), and IL-12/23 inhibitors, with demonstrated superior efficacy versus placebo for dactylitis resolution 2
JAK inhibitors (upadacitinib, tofacitinib) are also strongly recommended, showing similar efficacy to adalimumab for dactylitis at week 24, with a high level of evidence 2

NSAIDs are usually employed initially for symptomatic relief of dactylitis, with Level D evidence, and local corticosteroid injections can be used for rapid relief 1, 5

Topical therapy for scalp should include high-potency topical corticosteroid, calcipotriene foam or calcipotriene plus betamethasone dipropionate gel, with a critical caveat to avoid combining salicylic acid with calcipotriene simultaneously due to acidic pH inactivating calcipotriene 6, 7

Conventional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, should not be used as monotherapy, with only Level D evidence for dactylitis, and methotrexate receiving only a conditional recommendation for dactylitis treatment 1, 2, 5
Systemic corticosteroids should not be used as monotherapy, as they can cause psoriasis flares during or after taper, with a high risk of adverse effects 3, 7, 8

Cyclosporine should be limited to less than 12 consecutive months if used, though it is not first-line for this presentation, with a moderate level of evidence 1, 5
After achieving scalp control, transition to weekend-only high-potency corticosteroid with weekday vitamin D analogue therapy to minimize corticosteroid exposure, with a low level of evidence 7